Open AccessEvaluation of Trimetazidine in Angina Pectoris by Echocardiography and Radionuclide Angiography: A Meta‐Analysis of Randomized, Controlled Trials
Author(s) -
Hu Bo,
Li Wei,
Xu Tao,
Chen Tao,
Guo Jin
Publication year - 2011
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.20888
Subject(s) - medicine , trimetazidine , ejection fraction , jadad scale , cardiology , radionuclide angiography , angina , meta analysis , placebo , randomized controlled trial , stroke volume , myocardial infarction , heart failure , cochrane library , alternative medicine , pathology
Background: The objective of this meta‐analysis was to evaluate the efficacy of the metabolic agent trimetazidine (TMZ) as monotherapy in the treatment of stable angina pectoris, from echocardiography and radionuclide angiography data. Hypothesis: Treatment with TMZ proved to be as effective as other first‐line antianginal agents for coronary patients, and it provided additional efficacy in combination with hemodynamic agents. Methods: A search of the literature published between 1965 and 2008 was performed on the MEDLINE and EMBASE databases. Only randomized, controlled trials were included in this meta‐analysis. Patients had to be treated for at least 2 weeks with data on the following 4 parameters at baseline and at the end of the treatment period: left ventricular ejection fraction (LVEF), LV end‐diastolic volume (LVEDV), LV end‐systolic volume (LVESV), and wall motion score index (WMSI). The quality of the trials was assessed by the Jadad score. Results: Eleven clinical studies meeting our criteria were analyzed. Results showed that TMZ significantly improved LVEF, with a mean increase of 6.88% (95% confidence interval [CI]: 5.50–8.25), and significantly reduced LVESV by 11.58 mL (95% CI: 5.79–17.37) and WMSI by 0.23 (95% CI: 0.07–0.38). Changes in LVEDV were variable. In both the long term and the short term, TMZ can improve LV function. The efficacy was unchanged in patients with diabetes mellitus. Conclusions: This meta‐analysis confirmed the efficacy of TMZ monotherapy in improving LV function compared with placebo. © 2011 Wiley Periodicals, Inc. The authors have no funding, financial relationships, or conflicts of interest to disclose.